Evaluation of a digital therapy programme for the treatment of primary arterial hypertension: eXPLORE - study protocol for a fully decentralised randomised controlled feasibility study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
05 Sep 2024
Historique:
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 5 9 2024
Statut: epublish

Résumé

Hypertension is a major cause of premature death worldwide as it is an important risk factor for coronary artery disease, myocardial infarction, heart failure and stroke. Although an estimated 1.3 billion adults suffer from hypertension, less than half of them are diagnosed correctly and therefore receive sufficient treatment. Furthermore, only one fifth of those treated reach the therapy target of normotension. This significant deficit underlines the need for new therapy concepts to improve long-term health outcomes. Several studies have shown positive effects of digital health programmes in the disease management of ambulatory, long-term hypertension treatment. More research is needed to explore the abilities of digital health programmes as an innovative pathway in ambulatory healthcare.The eXPLORE study aims to evaluate the feasibility of a clinical trial on the impact of a supplementary digital therapy programme for the treatment of primary arterial hypertension. The eXPLORE study collects data in the setting of a prospective randomised controlled trial to evaluate methodological feasibility for larger-scaled follow-up research. The study compares a digital therapy programme using a smartphone application that is based on functions and algorithms creating tasks and recommendations based on individual health data to standard care for the treatment of primary arterial hypertension. The study period is 180 days, with a 90-day in-life phase followed by a 90-day follow-up phase. Baseline and follow-up data (3 months, 6 months follow-up) of all participants included is collected via questionnaire surveys as well as self-administered blood pressure monitoring. Patient inclusion, initial data acquisition and follow-up were carried out in an innovative remote setting. The study was initiated in November 2022 and is currently ongoing. Study outcome measures are changes in mean blood pressure, health literacy and self-sufficient health behaviour. The eXPLORE study is carried out in accordance with all applicable legal regulations. Cost-effectiveness is assured by continuous evaluation and documentation over the course of the study. All health-relevant data from the eXPLORE study will be provided for analyses and publication to the investigators of LMU Hospital. The study was approved by the local ethics committee of LMU Munich (project nr.: 22-0115). NCT05580068. 1.5, 28.08.2023.

Identifiants

pubmed: 39237273
pii: bmjopen-2023-081347
doi: 10.1136/bmjopen-2023-081347
doi:

Banques de données

ClinicalTrials.gov
['NCT05580068']

Types de publication

Journal Article Clinical Trial Protocol

Langues

eng

Sous-ensembles de citation

IM

Pagination

e081347

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: PW is an employee of iATROS.

Auteurs

Jenny Schlichtiger (J)

Medizinische Klinik und Poliklinik 1, LMU Klinikum der Universität München, Munich, Germany.
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, LMU Klinikum der Universität München, Munich, Germany.

Anna Strüven (A)

Medizinische Klinik und Poliklinik 1, LMU Klinikum der Universität München, Munich, Germany.
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, LMU Klinikum der Universität München, Munich, Germany.

Steffen Massberg (S)

Medizinische Klinik und Poliklinik 1, LMU Klinikum der Universität München, Munich, Germany.
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, LMU Klinikum der Universität München, Munich, Germany.

Georges von Degenfeld (G)

I. Medizinische Klinik, Universitätsklinikum Augsburg, Augsburg, Germany.

Alexander Leber (A)

Isar Herzzentrum, Munich, Germany.

Paul Weyh (P)

iATROS GmbH, Munich, Germany.

Julia Meyer (J)

iATROS GmbH, Munich, Germany.

Stefan Brunner (S)

Medizinische Klinik und Poliklinik 1, LMU Klinikum der Universität München, Munich, Germany.
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, LMU Klinikum der Universität München, Munich, Germany.

Christopher Stremmel (C)

Medizinische Klinik und Poliklinik 1, LMU Klinikum der Universität München, Munich, Germany christopher.stremmel@med.uni-muenchen.de.
DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, LMU Klinikum der Universität München, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH